In melanoma, anti-PD-1 therapy induced the regression of 20% of the tumors, while a synergistic antitumor effect was observed when anti-PD-1 was used in combination with anti-TNFα antibodies causing tumor regression of 75% (191). Here, TNF is linked to melanoma.